Share >  
Share
Share on Tumblr

Forest Laboratories

News »

   latest by relevance
Forest settles Alzheimer's drug patent suits
Jul 23, 2010 at 08:26 | Source: Reuters
Forest Laboratories Inc said it and Germany's Merz Pharma reached settlement agreements for all patent litigation over their Namenda Alzheimer's drug that will keep cheaper generic versions of the medicine off the US market until January 2015.
Sun Pharma gets USFDA nod for Namenda generic
May 06, 2010 at 19:47 | Source: Moneycontrol.com
Drug major Sun Pharma has received US Food and Drug Administration (FDA) approval to market a generic version of Forest Laboratories Namenda generic, Memantine. These have an annual sale of USD 1.2 billion.
Orchid Chem settles litigation with Forest Labs for Namenda
Apr 29, 2010 at 15:41 | Source: CNBC-TV18
Orchid Chemicals & Pharmaceuticals has settled its litigation with Forest Laboratories for Namenda, reports CNBC-TV18. The market size for the Namenda generic is USD 950 million, the company said.
Sun Pharma gets US nod for Namenda generic
Apr 10, 2010 at 16:17 | Source: Reuters
Indian drugmaker Sun Pharmaceuticals said on Saturday its unit had received tentative US regulatory approval to market a generic version of Forest Laboratories' Namenda tablets.
Lupin may launch 6-7 products next quarter
Dec 23, 2009 at 11:11 | Source: CNBC-TV18
Pharmaceutical company Lupin expects a good market share despite competition, S Ramesh, Chief Financial Officer of the company told CNBC-TV18 in an interview. On the companys growth, he said that Lupin is expected to launch six-seven products in next quarter.
Lupin settles Hatch-Waxman litigation with Forest Labs
Dec 22, 2009 at 18:59 | Source: CNBC-TV18
Lupin has settled its litigation with Hatch Waxman regarding Memantine tablets. This could mean a potential upside of more than $200 million dollars for the company. However the agreement states Lupin can commercially launch this product post 2015, reports CNBC-TV18s Priyanka Ghosh.

Videos »
Lupin may launch 6-7 products next quarter
Lupin settles Hatch-Waxman litigation with Forest Labs
more »

Photos »

  /  
News across the web »
Amylin analysts advise caution amid stock run-up
BOSTON (MarketWatch) -- Analysts on Wednesday advised Amylin Pharmaceuticals investors to proceed with caution given the massive run-up in stock on a report that Bristol-Myers Squibb had made a lucra...
Mar 29, 2012 at 04:17 | Source: Market Watch
Live: Sensex down 243 pts as repo rate remains unchanged
3.30 p.m: Markets traded near the day’s low as political uncertainty, economic survey and the central bank’s credit policy all weighed on the markets. Sensex closed the day 243 points low...
Mar 15, 2012 at 18:06 | Source: FirstPost
What If Antibiotics Stop Working? Cataclysm
A panel at the World Economic Forum is going to address what happens if all of our antibiotics fail. The results are more far-reaching than you might at first think. For instance, many types of surge...
Jan 19, 2012 at 21:41 | Source: Forbes
US stock index futures signal strong gains
U.S. stock index futures pointed to a higher open on Wall Street on Tuesday following a long holiday weekend, with futures for the S&P 500 up 1.01 percent, Dow Jones futures up 0.95 percent and Nasda...
Jan 18, 2012 at 00:12 | Source: Economic Times
Stocks to watch Tuesday: Carnival, Georgia Gulf
WASHINGTON (MarketWatch) — Among the stocks that could see active trade in Tuesday’s session are Carnival Corp., Georgia Gulf Corp. and Lions Gate Entertainment Corp. Earnings season begins to ge...
Jan 17, 2012 at 17:42 | Source: Market Watch
more »
Related News »
Forest Labs scraps agent obtained through merger
Forest Laboratories Inc. (NYSE:FRX) has discontinued development of an experimental agent for cardiovascular imaging procedures. In an annual report filed Friday with the U.S. Securities and Exchange Commission, Forest said it decided to ...
May 25, 2012 at 20:00 | Source: Marketwatch
Forest Laboratories (FRX) Breaks Through Resistance at $34.02
Shares of Forest Laboratories (NYSE:FRX) opened today above their pivot of $33.74 and have already reached the first level of resistance at $34.02. Analysts will be watching for a cross of the next upside pivot targets of $34.17 and $34.60. Forest ...
May 17, 2012 at 14:18 | Source: Financial News Network Online
Data from Almirall, Forest Labs’ aclidinium studies on COPD to be presented at ATS conference
Forest Laboratories, Inc. (NYSE: FRX) and Almirall, S.A. (ALM.MC) today announced that they will present aclidinium-related data in 1 poster discussion session and 3 poster presentations at the American Thoracic Society (ATS) International ...
May 19, 2012 at 10:20 | Source: News-Medical.Net
Analyst Research on Teva Pharmaceutical Industries Limited and Forest Laboratories Inc. - Mixed Results for Drug Manufacturers
JOHANNESBURG, SOUTH AFRICA — www.stockcall.com/ offers investors comprehensive research on the Drug Manufacturers - Other industry and has completed analytical research on Teva Pharmaceutical Industries Limited (NASDAQ: TEVA) and Forest ...
May 16, 2012 at 12:18 | Source: msnbc.com
Potential Forest Laboratories (FRX) Trade Targets 18.93% Return
Thursday, May 17, 2012... Forest Laboratories (NYSE:FRX) closed Wednesday's directionless trading session at $33.87. In the past year, the stock has hit a 52-week low of..... Friday, May 11, 2012... Forest Laboratories Inc. (NYSE: FRX) closed Thursday's ...
May 23, 2012 at 11:48 | Source: Market Intelligence Center
Forest Laboratories, Inc. : Ironwood and Forest to Present 17 Linaclotide-Related Abstracts at Digestive Disease Week® 2012
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) today announced they will present linaclotide-related data in one oral presentation and 16 poster presentations during Digestive Disease Week (DDW) 2012 being held in ...
May 14, 2012 at 12:06 | Source: 4-traders (press release)
Change in Directors or Principal Officers, Financial Statements and Exhib
On May 7, 2012, the Board of Directors (the "Board") of Forest Laboratories, Inc. (the "Company") approved the Forest Laboratories, Inc. Annual Incentive Compensation Plan (the "Incentive Plan"). The Incentive Plan is intended to provide a cash-based ...
May 11, 2012 at 18:58 | Source: Yahoo! Finance
Antipsychotic Effective for Treating Bipolar Mania
May 23, 2012 (Philadelphia, Pennsylvania) — The antipsychotic cariprazine (Forest Laboratories Inc, Gedeon Richter Plc) is effective for treating mania in bipolar disorder (BD), new research suggests. In results from a large phase 3 trial presented here ...
May 23, 2012 at 19:05 | Source: Medscape News
Ironwood and Forest to Present 17 Linaclotide-Related Abstracts at Digestive Disease Week(R) 2012
CAMBRIDGE, Mass. & NEW YORK, May 14, 2012 (BUSINESS WIRE) -- Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) and Forest Laboratories, Inc. (NYSE:FRX) today announced they will present linaclotide-related data in one oral presentation and 16 poster ...
May 14, 2012 at 10:19 | Source: Marketwatch
Forest and Almirall to Present Aclidinium Bromide Clinical Data at the American Thoracic Society (ATS) International Conference
Forest Laboratories, Inc. (NYSE:FRX - News) and Almirall, S.A. (ALM.MC) today announced that they will present aclidinium-related data in 1 poster discussion session and 3 poster presentations at the American Thoracic Society (ATS) International ...
May 18, 2012 at 09:52 | Source: Yahoo Finance

Follow moneycontrol.com

Facebook Twitter Google Plus RSS Wap SMS SMS Alert iPad iPhone Blackberry OVI Android Window